Neurent Medical announced that it received FDA 510(k) clearance for its next-generation Neuromark system for chronic rhinitis.
The latest advancement in the Neuromark platform delivers a new level of control, confirmation and confidence for otolaryngologists.
Galway, Ireland-based Neurent designed the system to optimize the treatment of posterior nasal nerves. It provides real-time feedback, guides proper electrode placement and confirms successful treatment delivery.
Neuromark features a flexible shaft and atraumatic leaflets that conform to the patient anatomy. This enables physicians to reach challenging areas in the nasal cavity while maximizing treatment coverage. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals. This addresses the key symptoms of chronic rhinitis, such as persistent nasal congestion and rhinorrhea (runny nose).
Neurent says the FDA clearance paves the way for broader U.S. availability of Neuromark as it continues its mission to redefine the standard of care for chronic rhinitis.
“We have just completed a highly successful commercial validation phase, positioning the Neuromark system at the forefront of chronic rhinitis care,” said Brian Shields, CEO of Neurent Medical. “During this phase, we collaborated with leading general ENT and rhinology specialists across both private practice and academic settings. Their insights were instrumental in shaping this next-generation system. I am incredibly proud of how their feedback translated into meaningful technological improvements.
“This milestone highlights our continued commitment to innovations that empower ENTs to treat patients with greater confidence.”
